Stocks and Investing Stocks and Investing
Fri, January 24, 2025
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Asset Entities Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. tis Therapeutics Holdings, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. g of Digital Brands Group, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Big Lots, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Prestige Wealth Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. of The Oncology Institute, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. Diamondhead Casino Corporation in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of RF Acquisition Corp. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. lling of Bionano Genomics, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of GeoVax Labs, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. neral Enterprise Ventures, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of G6 Materials Corp. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Blackboxstocks Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. gularity Future Technology Ltd. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Nikola Corporation in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of VerifyMe, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Rail Vision Ltd. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. ing of Nevada Canyon Gold Corp. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of IMAC Holdings, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Ainos, Inc. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. of Quoin Pharmaceuticals, Ltd. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Autris in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial selling of Vivic Corp. in recent trading
[ Fri, Jan 24th ] - WOPRAI
As of Jan 24th, 2025, there has been substantial .. f Chanson International Holding in recent trading
[ Fri, Jan 24th ] - Morningstar
7 Retirement Must-Knows for 2025
[ Fri, Jan 24th ] - WOPRAI
31 Earnings Releases for Jan 24th, 2025
Thu, January 23, 2025
[ Thu, Jan 23rd ] - MSN
Avidity Biosciences CFO sells $93,985 in stock
[ Thu, Jan 23rd ] - MSN
2 'Strong Buy'-Rated Dividend Stocks With Yields Above 7% for 2025
[ Thu, Jan 23rd ] - MSN
Altimmune's SWOT analysis: pemvidutide potential drives stock outlook

Altimmune's SWOT analysis: pemvidutide potential drives stock outlook


Published on 2025-01-23 22:21:09 - MSN
  Print publication without navigation

  • Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on developing treatments for liver disease and obesity, has been garnering attention from analysts and investors alike.

The article from MSN Money discusses Altimmune, Inc., a clinical-stage biopharmaceutical company, focusing on its SWOT analysis and the potential impact of its lead product candidate, pemvidutide, on its stock outlook. Pemvidutide is a GLP-1/glucagon dual receptor agonist aimed at treating obesity and non-alcoholic steatohepatitis (NASH). Strengths include a promising pipeline with pemvidutide showing significant weight loss in early trials, and a robust intellectual property portfolio. Weaknesses highlight the company's reliance on the success of pemvidutide, with no other products currently generating revenue, and its history of net losses. Opportunities are vast, given the growing market for obesity and NASH treatments, potential partnerships, and the possibility of expanding into other metabolic diseases. Threats include intense competition from larger pharmaceutical companies, potential clinical trial failures, and regulatory hurdles. The article suggests that while pemvidutide's potential could drive stock value, investors should consider the inherent risks associated with clinical-stage biotech companies.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/general/altimmune-s-swot-analysis-pemvidutide-potential-drives-stock-outlook/ar-AA1xLijY ]
Contributing Sources